ReviewFrontiers in cellular neuroscience2021
Myelin Repair: From Animal Models to Humans.
Review in Frontiers in cellular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Decoding chemotherapy-induced peripheral neuropathy: ion channels, disease models, and future directions.Frontiers in pharmacology · 2026Review
- Enhancing oligodendrocytes generation and myelin renewal by vitamin C mitigate Parkinson-relevant phenotypes in a murine model of Parkinson's disease.Frontiers in cellular neuroscience · 2026Article
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Advances in tissue optical clearing for 3D imaging in large animal.Frontiers of optoelectronics · 2025Review
- How do different cell populations orchestrate myelin regeneration?Biochemical Society transactions · 2025Review
- Demyelination and impaired oligodendrogenesis in the corpus callosum following lead exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- p38γ MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.Brain : a journal of neurology · 2024Article
- The Genomic Intersection of Oligodendrocyte Dynamics in Schizophrenia and Aging Unravels Novel Pathological Mechanisms and Therapeutic Potentials.International journal of molecular sciences · 2024Review
- The aminosteroid U73122 promotes oligodendrocytes generation and myelin formation.Acta pharmacologica Sinica · 2024Article
- Adult human neurogenesis: A view from two schools of thought.IBRO neuroscience reports · 2023Review
- Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System.Laboratory investigation; a journal of technical methods and pathology · 2023Article
- Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination.Neural regeneration research · 2023Article
- Effectiveness of various diet patterns among patients with multiple sclerosis.Postepy psychiatrii neurologii · 2023Review
- Potential biological contributers to the sex difference in multiple sclerosis progression.Frontiers in immunology · 2023Article
- Rapid differentiation of hiPSCs into functional oligodendrocytes using an OLIG2 synthetic modified messenger RNA.Communications biology · 2022Article
- Review
- Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Protein Tyrosine Phosphatase Receptor Type Z in Central Nervous System Disease.International journal of molecular sciences · 2022Review
- Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.Biomedicines · 2022Review
- Brain Plasticity in Humans and Model Systems: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is widely thought that brain repair does not occur, but myelin regeneration provides clear evidence to the contrary. Spontaneous remyelination may occur after injury or in multiple sclerosis (MS). However, the efficiency of remyelination varies considerably between MS patients and between the lesions of each patient. Myelin repair is essential for optimal functional recovery, so a profound understanding of the cells and mechanisms involved in this process is required for the development of new therapeutic strategies. In this review, we describe how animal models and modern cell tracing and imaging methods have helped to identify the cell types involved in myelin regeneration. In addition to the oligodendrocyte progenitor cells identified in the 1990s as the principal source of remyelinating cells in the central nervous system (CNS), other cell populations, including subventricular zone-derived neural progenitors, Schwann cells, and even spared mature oligodendrocytes, have more recently emerged as potential contributors to CNS remyelination. We will also highlight the conditions known to limit endogenous repair, such as aging, chronic inflammation, and the production of extracellular matrix proteins, and the role of astrocytes and microglia in these processes. Finally, we will present the discrepancies between observations in humans and in rodents, discussing the relationship of findings in experimental models to myelin repair in humans. These considerations are particularly important from a therapeutic standpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.